Madrigal registers Phase 4 safety study of Rezdiffra with diabetes drugs in MASH patients
Madrigal Pharmaceuticals listed a new Phase 4 trial testing Rezdiffra alongside pioglitazone or dapagliflozin in adults with MASH and F2-F3 fibrosis, not yet recruiting.
Madrigal Pharmaceuticals had one item posted to ClinicalTrials.gov this week.
- Madrigal registered NCT07848191, a Phase 4, open-label study of Rezdiffra (resmetirom) combined with common diabetes medications in adults with MASH and moderate-to-advanced (F2-F3) fibrosis. The trial will evaluate concomitant use of ACTOS/pioglitazone and FARXIGA/dapagliflozin1, with approximately 25 participants planned for each of six cohorts, for a maximum planned enrollment of approximately 150 participants1. The study is listed as not yet recruiting, with an estimated start of 2026-09 and estimated primary completion in 2027-11.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.